ABPI Logo
  • Developing medicines
    • Responding to COVID-19
    • Clinical trials and research
    • Building a thriving environment for medicine discovery
    • UK-EU Future Relationship
    • Life Sciences Industrial Strategy
    • ABPI Medical Representatives Exam
  • Accessing medicines
    • How medicines are priced in the UK
    • Working with the NHS
    • Supply chain
    • Antimicrobial resistance (AMR)
    • Vaccines
    • What is the NICE Methods Review?
    • Rare diseases: Facing three challenges
  • Our ethics
    • ABPI Code of Practice
    • Disclosure UK
    • Appropriate prescribing
    • Patient & public involvement
  • Member representation
    • Events
    • Full membership
    • Working with our members​
    • ABPI Members List
    • Membership benefits
  • Who We Are
  • Media
  • Publications
  • Facts and Figures
  • Contact Us
MY ABPI LOGIN
 
  • The Association of the British Pharmaceutical Industry
  • Developing medicines
  • Clinical trials and research
  • ABPI Clinical Trials Report 2020 - How the UK can transform the clinical research environment
  • Conclusion

Conclusion

The pharmaceutical industry operates globally; these companies will continue to place their investment where they feel confident that their research can be efficiently and successfully delivered.

Countries capable of approving and setting up cost-effective clinical trials efficiently and delivering on patient recruitment targets, whilst maintaining high patient safety standards, will succeed in attracting commercial investment in their clinical research environments.

By embracing new and innovative approaches to clinical research design, delivery, and regulation, including data and digital technologies, the UK has the opportunity to transform how clinical trials are conducted and to maximise benefits for the NHS, patients and the economy.

A key part of this transformation will be bringing the NHS into the 21st century, with state-of-the- art infrastructure and a research culture that is embedded in daily processes and across the workforce.

Following the COVID-19 pandemic, the UK must address the immediate challenges that lie ahead, ensuring that as it takes the stage on an international platform in 2021, the right interventions are implemented to deliver on its commitment of becoming a ‘science superpower’.

ABPI Clinical Trials Report 2020 - How the UK can transform the clinical research environment

  • Executive summary
  • Introduction: The time for transformation is now
  • A benchmark for global clinical research
  • Global R&D by disease area: Where does the UK do best?
  • Beyond COVID-19: Restart, Recovery and Resilience
  • Recommendations
  • Conclusion
  • References
  • Data collection methodology & Appendices

ABPI

The Association of the British Pharmaceutical Industry is a company limited by guarantee registered in England and Wales 
(registered number 09826787) and its registered office is at 7th Floor Southside,105 Victoria Street, London, SW1E 6QT.
Telephone +44 (0) 207 9303477

© ABPI 2021
  • Twitter Logo
  • LinkedIn
  • YouTube Logo

Devolved Nations

  • Cymru Wales
  • Northern Ireland
  • Scotland

Quick Links

  • ABPI Exam
  • Disclosure UK
  • Frequently Asked Questions
  • Careers
  • Schools
  • Acronym buster

Website Info

  • Terms and conditions
  • Accessibility
  • Cookie Policy

Prescription Medicines Code of Practice Authority (PMCPA)

The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of ABPI which is a company registered in England and Wales (registered number 09826787) with its registered office at 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT.

Office of Health Economics (OHE)

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT. OHE provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.